about
Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo.Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens.Novel viral vectors in infectious diseases.Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology.Exchange of Genetic Sequences Between Viruses and Hosts.Enhanced immunotherapy by combining a vaccine with a novel murine GITR ligand fusion protein.Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?Are We Prepared in Case of a Possible Smallpox-Like Disease Emergence?E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.Challenges and Achievements in Prevention and Treatment of Smallpox.40 Years without Smallpox.Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic.Distinct Immunogenicity and Efficacy of Poxvirus-based Vaccine Candidates against Ebola Virus expressing GP and VP40 Proteins.Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase.A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis.Herd Immunity to Ebolaviruses Is Not a Realistic Target for Current Vaccination Strategies.Tracking Modified Vaccinia Virus Ankara in the Chicken Embryo: In Vivo Tropism and Pathogenesis of Egg InfectionsRemoval of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression
P2860
Q38619090-894A3246-9499-4DA7-A7E6-8205644EA846Q38667931-47970112-2774-4281-A464-308602CFFB97Q40059020-AF88D3DE-6A8D-416B-96B0-F3729CB6291BQ40117821-06129874-A63D-468F-A857-876346514609Q40183279-EBE5762C-DAAD-418A-B3BA-45A1703A8366Q44302880-32D5FCE6-5092-462E-9EA2-2F3E38038517Q45325213-8E42C12F-9F28-4436-A0EE-47A62E105FF0Q47116100-F612BBD1-3240-4CB8-85C8-585CA6D83601Q47233214-80CC7C44-CB60-4CAA-98CB-ED95A4B0ED1BQ47547852-8C4BA4EE-559B-47CB-9A15-6C9DB4C48D58Q47552709-AAEB37DD-CD38-4B25-8123-E8968E78C8FBQ47570091-7D95F733-554C-404E-9BFB-8EF2E7B85FC8Q51784219-2A2F4A3D-A8CC-4439-B270-6CF1128AFD6BQ52620757-555D99E3-D286-4055-A79F-BB15CD043C81Q53689031-519C2AAC-D4BA-4C34-9D5C-B875F4A809D3Q55241490-2068043D-255B-4440-8DB6-FB459CCFCBBCQ56557124-784E0B51-81E4-4D82-A8A7-45F49208937DQ56987707-000F3C3C-DA6A-470B-B96C-B190DCDD7D08
P2860
description
2017 nî lūn-bûn
@nan
2017 թուականին հրատարակուած գիտական յօդուած
@hyw
2017 թվականին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Modified Vaccinia Virus Ankara
@ast
Modified Vaccinia Virus Ankara
@en
Modified Vaccinia Virus Ankara
@nl
type
label
Modified Vaccinia Virus Ankara
@ast
Modified Vaccinia Virus Ankara
@en
Modified Vaccinia Virus Ankara
@nl
prefLabel
Modified Vaccinia Virus Ankara
@ast
Modified Vaccinia Virus Ankara
@en
Modified Vaccinia Virus Ankara
@nl
P1476
Modified Vaccinia Virus Ankara
@en
P2093
P304
P356
10.1016/BS.AIVIR.2016.07.001
P50
P577
2017-01-01T00:00:00Z